As of Oct. 5, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
Here’s the latest list of major overbought players in this sector.
On Sept. 28, Quantum-Si presented interim Proteus data at HUPO 2026. The protein analysis company described the results as a "step-change" in performance for its Proteus platform. The company’s stock gained around 89% over the past five days and has a 52-week high of $3.10.
RSI Value: 86.6
QSI Price Action: Shares of Quantum-Si gained 8.4% to close at $1.55 on Friday.
On Sept. 28, Kodiak Sciences announced that the primary endpoints were met for Zenkuda and tabirafusp-ted in the Phase 3 DAYBREAK study in patients with wet age-related macular degeneration. The company’s stock gained around 167% over the past month and has a 52-week high of $104.00.
RSI Value: 85.7
KOD Price Action: Shares of Kodiak Sciences fell 4.1% to close at $94.45 on Friday.
On Oct. 1, Iovance Biotherapeutics named Noah Berkowitz, M.D., Ph.D., as chief medical officer. The company’s stock gained around 62% over the past month and has a 52-week high of $15.30.
RSI Value: 80.2
IOVA Price Action: Shares of Iovance Biotherapeutics fell 0.1% to close at $14.22 on Friday.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.